Investor Presentaiton
Screening
Early Disease Detection
Minimal Residual Disease
Recurrence Detection & Surveillance
Therapy Selection
Advanced Cancer Care
>120M
Average-Risk
Individuals
Do I have cancer?
GUARDANT™
>15M
Early-Stage Patients
and Survivors
Cancer
Detection
Surgery
+/- Adjuvant
Do I still have cancer?
>700K
Advanced Cancer
Patients
INVESTOR 20
DAY 23
Recurrence
1st Line Tx
2nd Line Tx
+TX
Has my cancer returned?
Am I responding to therapy?
What kind of therapy is best for me?
Shield™ LDT assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods. The Shield
assay is a screening assay and not a replacement for a diagnostic colonoscopy. AACR Study, Cancer Prev Res (2020) 13 ACS Cancer Treatment
& SurvivorshipFacts & Figures 2019-2021 American Cancer Society Cancer Facts and Statistics; SEER
11View entire presentation